SCHEMBL79130

SCHEMBL79130

CC(C)(C)c1ocnc1/C=c1\[nH]c(=O)/c(=C/c2ccc(Br)o2)[nH]c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 3/20 0.38
▸ CYP2C9 P11712 3/20 0.38
▸ CYP2C19 P33261 3/20 0.38
▸ RAF1 P04049 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ CCNB1 P14635 1/20 0.38
▸ POLB P06746 7/20 0.34
▸ MAPT P10636 5/20 0.34
▸ TDP1 Q9NUW8 4/20 0.34
▸ L3MBTL1 Q9Y468 4/20 0.34
▸ MEN1 O00255 4/20 0.34
▸ KMT2A Q03164 4/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ APEX1 P27695 3/20 0.34
▸ RECQL P46063 3/20 0.34
▸ KDM4E B2RXH2 2/20 0.34
▸ NSD2 O96028 1/20 0.34
▸ DNMT1 P26358 1/20 0.34
▸ ESR1 P03372 1/20 0.34
▸ ESR2 Q92731 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL87490 1.00 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL88047 0.86 CYP1A2 (0.38) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL12727719 0.81 POLB (0.35) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL80217 0.80 CYP1A2 (0.61) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL79707 0.78 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL87483 0.78 CYP1A2 (0.47) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL66006 0.78 CYP1A2 (0.62) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL80720 0.78 CYP1A2 (0.62) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL83908 0.76 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19RAF1CDK1
SCHEMBL80677 0.76 CYP1A2 (0.44) CYP1A2CYP2C9CYP2C19RAF1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11633393-B2 Tubulin binding compounds and therapeutic use thereof BEYONDSPRING PHARMACEUTICALS, INC. (US) 2023-04-25 — — US disclosed
US-20200237754-A1 TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF BEYONDSPRING PHARMACEUTICALS, INC. 2020-07-30 — — US disclosed
US-8618292-B2 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. (US) 2013-12-31 — — US disclosed
US-20120277251-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE NEREUS PHARMACEUTICALS, INC. (US) 2012-11-01 — — US disclosed
US-20120277251-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE NEREUS PHARMACEUTICALS, INC. (US) 2012-11-01 — — US disclosed
US-20120277251-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE NEREUS PHARMACEUTICALS, INC. (US) 2012-11-01 — — US disclosed
US-8247552-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2012-08-21 — — US disclosed
US-8247552-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2012-08-21 — — US disclosed
US-8247552-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2012-08-21 — — US disclosed
US-8129527-B2 cancer and non-cancer diseases associated with vascular proliferation; mitoxantrone resistant, taxol resistant cancers NEREUS PHARMACUTICALS, INC. (US) 2012-03-06 — — US disclosed
US-20110245260-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE NEREUS PHARMACEUTICALS, INC. (US) 2011-10-06 — — US disclosed
US-7919497-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2011-04-05 — — US disclosed
US-7919497-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2011-04-05 — — US disclosed
US-7919497-B2 Analogs of dehydrophenylahistins and their therapeutic use NEREUS PHARMACEUTICALS, INC. (US) 2011-04-05 — — US disclosed
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE BEYONDSPRING PHARMACEUTICALS, INC. 2008-09-11 — — US disclosed
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE BEYONDSPRING PHARMACEUTICALS, INC. 2008-09-11 — — US disclosed
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE BEYONDSPRING PHARMACEUTICALS, INC. 2008-09-11 — — US disclosed
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. 2007-04-05 — — US disclosed
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. 2007-04-05 — — US disclosed
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use BEYONDSPRING PHARMACEUTICALS, INC. 2007-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110245260-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE MKI67, HPGDS, HCCS CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885
US-20070078138-A1 Analogs of dehydrophenylahistins and their therapeutic use MKI67, HPGDS, HCCS CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885
US-20080221122-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THEAPEUTIC USE HPGDS, DHPS, HCCS CYP1A2 1594/4885CYP2C9 3869/4885CYP2C19 2655/4885
US-11633393-B2 Tubulin binding compounds and therapeutic use thereof TUBB6, TUBB1, TUBB CYP1A2 4665/4885CYP2C9 4752/4885CYP2C19 4805/4885
US-20200237754-A1 TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF TUBB6, TUBB1, TUBB CYP1A2 4665/4885CYP2C9 4752/4885CYP2C19 4805/4885
US-20120277251-A1 ANALOGS OF DEHYDROPHENYLAHISTINS AND THEIR THERAPEUTIC USE MKI67, HPGDS, HCCS CYP1A2 2042/4885CYP2C9 4257/4885CYP2C19 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback